Financial Ratios Trinity Biotech plc
Stocks
TRIB
US8964385046
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3707 USD | +3.00% |
|
-5.26% | -53.14% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.46 | -6.47 | -13.26 | -10.53 | -5.72 | |||||
Return on Total Capital | 5.54 | -8.08 | -17.71 | -15.71 | -9.07 | |||||
Return On Equity % | -73.21 | 3.29K | 282.24 | 105.58 | 69.76 | |||||
Return on Common Equity | -73.21 | 3.29K | 282.24 | 105.58 | 69.76 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 40.96 | 29.48 | 34.22 | 34.83 | 38.57 | |||||
SG&A Margin | 26.55 | 39 | 54.81 | 46.81 | 56.35 | |||||
EBITDA Margin % | 11.35 | -12.73 | -25.17 | -21.17 | -18.83 | |||||
EBITA Margin % | 10.04 | -14.01 | -26.63 | -22.26 | -21.79 | |||||
EBIT Margin % | 9.57 | -14.6 | -28.29 | -22.26 | -21.8 | |||||
Income From Continuing Operations Margin % | 1 | -54.83 | -64.87 | -50.71 | -85.36 | |||||
Net Income Margin % | 0.94 | -54.84 | -42.26 | -51.64 | -85.36 | |||||
Net Avail. For Common Margin % | 1 | -54.83 | -64.87 | -50.71 | -85.36 | |||||
Normalized Net Income Margin | 2.04 | -18.58 | -27.55 | -27.19 | -32.19 | |||||
Levered Free Cash Flow Margin | -0.83 | -11.33 | -22.58 | -11.42 | -25.57 | |||||
Unlevered Free Cash Flow Margin | 3.94 | -1.68 | -11.42 | 0.67 | -7.29 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.75 | 0.71 | 0.75 | 0.76 | 0.42 | |||||
Fixed Assets Turnover | 12.85 | 12.89 | 15.01 | 18.9 | 8.82 | |||||
Receivables Turnover (Average Receivables) | 5.22 | 5.42 | 4.59 | 4.88 | 3.72 | |||||
Inventory Turnover (Average Inventory) | 1.85 | 2.04 | 1.76 | 2.04 | 1.41 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.72 | 2.69 | 2.6 | 1.28 | 0.25 | |||||
Quick Ratio | 0.41 | 1.28 | 1.11 | 0.62 | 0.11 | |||||
Operating Cash Flow to Current Liabilities | 0.13 | -0.05 | -0.77 | -0.13 | -0.04 | |||||
Days Sales Outstanding (Average Receivables) | 69.86 | 67.4 | 79.6 | 74.97 | 98.22 | |||||
Days Outstanding Inventory (Average Inventory) | 197.31 | 178.68 | 207.17 | 179.32 | 259.2 | |||||
Average Days Payable Outstanding | 47.04 | 51.33 | 52.9 | 49.59 | 126.81 | |||||
Cash Conversion Cycle (Average Days) | 220.13 | 194.75 | 233.87 | 204.7 | 230.6 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -31.09K | -3.32K | -281.54 | -286.42 | -191.69 | |||||
Total Debt / Total Capital | 100.32 | 103.11 | 155.08 | 153.64 | 209.06 | |||||
LT Debt/Equity | -4.35K | -3.23K | -273.59 | -279.32 | -37.75 | |||||
Long-Term Debt / Total Capital | 14.02 | 100.41 | 150.7 | 149.84 | 41.17 | |||||
Total Liabilities / Total Assets | 100.27 | 102.36 | 140.29 | 134.06 | 168.45 | |||||
EBIT / Interest Expense | 1.25 | -0.95 | -1.58 | -1.15 | -0.75 | |||||
EBITDA / Interest Expense | 1.57 | -0.79 | -1.41 | -1.09 | -0.64 | |||||
(EBITDA - Capex) / Interest Expense | 1.32 | -0.88 | -1.49 | -1.13 | -0.65 | |||||
Total Debt / EBITDA | 8.89 | -7.96 | -4.71 | -7.73 | -16.74 | |||||
Net Debt / EBITDA | 6.56 | -7.24 | -4.46 | -7.34 | -16.12 | |||||
Total Debt / (EBITDA - Capex) | 10.61 | -7.1 | -4.46 | -7.5 | -16.56 | |||||
Net Debt / (EBITDA - Capex) | 7.84 | -6.45 | -4.22 | -7.12 | -15.95 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -8.84 | -19.56 | -9.1 | 8.31 | -28.87 | |||||
Gross Profit, 1 Yr. Growth % | -21.62 | -42.1 | 12.64 | 10.24 | -21.24 | |||||
EBITDA, 1 Yr. Growth % | -46.77 | -190.26 | 27.52 | -8.02 | -36.73 | |||||
EBITA, 1 Yr. Growth % | -50.58 | -212.21 | 19.9 | -8.61 | -30.37 | |||||
EBIT, 1 Yr. Growth % | -51.75 | -222.68 | 19.01 | -14.03 | -30.34 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -115.45 | -4.51K | -15.41 | -15.33 | 19.73 | |||||
Net Income, 1 Yr. Growth % | -113.7 | -4.79K | -41.43 | 32.35 | 17.58 | |||||
Normalized Net Income, 1 Yr. Growth % | -74.2 | -834.52 | 0.98 | 7.49 | -15.79 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -113.9 | -3.14K | -25.45 | -62.63 | 0.6 | |||||
Accounts Receivable, 1 Yr. Growth % | -33.83 | -5.12 | -15.64 | 22.34 | -30.18 | |||||
Inventory, 1 Yr. Growth % | -3.63 | -22.73 | -11.42 | -2.8 | -2.82 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -30.76 | -3.99 | -66.7 | 144.24 | 14.74 | |||||
Total Assets, 1 Yr. Growth % | -8.82 | -22.53 | -35.47 | 73.79 | 1.82 | |||||
Tangible Book Value, 1 Yr. Growth % | -17.73 | 9.75 | 22.89 | 161.08 | 60.74 | |||||
Common Equity, 1 Yr. Growth % | -85.62 | 582.13 | 1K | 46.9 | 104.6 | |||||
Cash From Operations, 1 Yr. Growth % | -44.27 | -106.96 | 1.15K | -63.74 | 41.47 | |||||
Capital Expenditures, 1 Yr. Growth % | -43.52 | -39.24 | -27.07 | -49.56 | -78.27 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -112.33 | 995.38 | 26.37 | -44.87 | 59.31 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -62.38 | -134.38 | 120.19 | -106.46 | -871.07 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 1.39 | -14.37 | -16.31 | -0.78 | -12.23 | |||||
Gross Profit, 2 Yr. CAGR % | -0.06 | -32.63 | -23.75 | 11.43 | -6.82 | |||||
EBITDA, 2 Yr. CAGR % | 44.15 | -33.49 | 24.84 | 7.78 | -23.72 | |||||
EBITA, 2 Yr. CAGR % | 91.3 | -27.35 | 43.42 | 4.2 | -20.23 | |||||
EBIT, 2 Yr. CAGR % | 597.42 | -23.06 | 57.79 | 0.72 | -22.61 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -82.1 | 161.13 | 346.42 | -15.37 | 0.69 | |||||
Net Income, 2 Yr. CAGR % | -82.6 | 153.37 | 423.92 | -11.96 | 24.75 | |||||
Normalized Net Income, 2 Yr. CAGR % | -27.14 | 37.67 | 548.37 | 3.89 | -4.86 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -83.1 | 105.55 | 229.89 | -47.21 | -35.36 | |||||
Accounts Receivable, 2 Yr. CAGR % | -16.56 | -20.77 | -10.54 | 1.59 | -7.58 | |||||
Inventory, 2 Yr. CAGR % | -4.63 | -13.71 | -17.27 | -7.21 | -2.81 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -20.19 | -18.47 | -43.46 | -9.82 | 67.4 | |||||
Total Assets, 2 Yr. CAGR % | -4.76 | -15.96 | -29.3 | 5.9 | 33.02 | |||||
Tangible Book Value, 2 Yr. CAGR % | 7.33 | -4.98 | 16.14 | 79.12 | 104.86 | |||||
Common Equity, 2 Yr. CAGR % | -73.98 | -0.97 | 766.46 | 302.09 | 73.37 | |||||
Cash From Operations, 2 Yr. CAGR % | 56.33 | -80.31 | -6.56 | 113.32 | -28.37 | |||||
Capital Expenditures, 2 Yr. CAGR % | -7.87 | -41.42 | -33.43 | -39.35 | -66.9 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -68 | 16.21 | 136.89 | -16.81 | -6.28 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 3.2 | -64.04 | 74.11 | -62.52 | -29.4 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -1.42 | -6.14 | -17.71 | -8.8 | -11.2 | |||||
Gross Profit, 3 Yr. CAGR % | -2.79 | -16.68 | -26.3 | -13.78 | -0.74 | |||||
EBITDA, 3 Yr. CAGR % | -0.86 | 23.32 | -12.73 | 12.39 | -9.76 | |||||
EBITA, 3 Yr. CAGR % | -0.68 | 60.14 | -8.65 | 23.04 | -8.9 | |||||
EBIT, 3 Yr. CAGR % | 9.9 | 290.77 | -4.48 | 28.5 | -10.93 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -65.52 | 12.25 | 83.03 | 156.49 | -4.99 | |||||
Net Income, 3 Yr. CAGR % | -65.91 | 12.35 | 55.5 | 231.2 | -3.04 | |||||
Normalized Net Income, 3 Yr. CAGR % | -6.88 | 57.4 | 28.78 | 255.53 | -3.13 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -66.71 | -4.6 | 49.6 | 59.63 | -32.21 | |||||
Accounts Receivable, 3 Yr. CAGR % | -15.6 | -12.91 | -19.09 | -0.7 | -10.35 | |||||
Inventory, 3 Yr. CAGR % | -1.38 | -11.09 | -12.95 | -12.7 | -5.77 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 3.34 | -15.12 | -39.51 | -7.92 | -2.28 | |||||
Total Assets, 3 Yr. CAGR % | -7.79 | -11.1 | -23.04 | -4.58 | 4.52 | |||||
Tangible Book Value, 3 Yr. CAGR % | 2.35 | 8.13 | 3.53 | 52.14 | 72.77 | |||||
Common Equity, 3 Yr. CAGR % | -80.65 | -22.71 | 120.99 | 379.56 | 221.01 | |||||
Cash From Operations, 3 Yr. CAGR % | 22.34 | -44.6 | -21.35 | -31.84 | 86.03 | |||||
Capital Expenditures, 3 Yr. CAGR % | -37.79 | -19.81 | -36.98 | -39.31 | -56.92 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -62.26 | 3.91 | 26.94 | 45.39 | 3.31 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -31.13 | -28.46 | -12.63 | -42.18 | 2.69 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -1.37 | -5.48 | -10.15 | -7.41 | -15.56 | |||||
Gross Profit, 5 Yr. CAGR % | -2.62 | -12.05 | -14.04 | -10.87 | -19.05 | |||||
EBITDA, 5 Yr. CAGR % | -6.1 | -2.27 | 5.73 | 20.74 | -17.47 | |||||
EBITA, 5 Yr. CAGR % | -3.73 | 3.59 | 9.69 | 39.97 | -13.63 | |||||
EBIT, 5 Yr. CAGR % | 1.37 | 14.79 | 19.12 | 137.07 | -12.34 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -52.54 | 1.18 | 10.23 | 1.49 | 44.11 | |||||
Net Income, 5 Yr. CAGR % | -61.29 | 0.36 | 1.69 | 1.91 | 42.38 | |||||
Normalized Net Income, 5 Yr. CAGR % | -12.86 | 46.71 | 46.22 | 36.26 | 13.97 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -52.65 | -7.55 | -2.33 | -23.79 | 6.94 | |||||
Accounts Receivable, 5 Yr. CAGR % | -5.58 | -7.5 | -13.61 | -7.37 | -14.67 | |||||
Inventory, 5 Yr. CAGR % | -2.22 | -7.26 | -8.07 | -9.56 | -9.03 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -15.08 | -0.41 | -18.81 | -13.04 | -9.11 | |||||
Total Assets, 5 Yr. CAGR % | -13.78 | -13.75 | -17.08 | -4.65 | -4.21 | |||||
Tangible Book Value, 5 Yr. CAGR % | -22.92 | -10.31 | 7.66 | 32.32 | 36.02 | |||||
Common Equity, 5 Yr. CAGR % | -68.85 | -49.34 | -11.48 | 49.49 | 100.55 | |||||
Cash From Operations, 5 Yr. CAGR % | 5.29 | -36.96 | 9.84 | -5 | -24.24 | |||||
Capital Expenditures, 5 Yr. CAGR % | -15.54 | -25.63 | -36.08 | -28.28 | -51.29 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -15.3 | -5.25 | -2.26 | -1.43 | 12.28 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 17.65 | -30.41 | -10.35 | -34.52 | -19.99 |
- Stock Market
- Stocks
- TRIB Stock
- Financials Trinity Biotech plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















